Enzolytics Inc (ENZC)

[falon]

darron427,

ENZC HAS to go through the regulatory PROTOCOLS to SAFELY prove their technology. They already went through clinical trials for ITV-1 in Buglaria with positive results so we already know where this is headed.

Here is an example of how another terd turn out when they went through the regulatory protocols and are on the verge of an IND.

2013:

Scorpion Venom: Can It Really Cure What Ails You?
Dominican-based company promises scorpion venom drug can help fight cancer.

Russian émigré Dr. Arthur Mikaelian and his company, Medolife, produce a drug called Escozine, whose sole active ingredient is blue scorpion venom. Medolife said Escozine is an effective cancer treatment because a peptide in the venom called chlorotoxin -- the same chemical that paralyzes prey -- also happens to target and kill cancer cells.

Dr. Len Lichtenfeld, the deputy medical director of the American Cancer Society, is skeptical of the cancer-curing properties of Escozine and cautioned against patients substituting alternative medicines for traditional cancer treatments, such as radiation and chemotherapy.

"There's no reasonable scientific evidence to show that this drug works in treating patients with cancer," Lichtenfeld said.

In the company's eight-year clinical study, which enrolled 8,302 cancer patients with varying disease type and severity, Escozine was found to have a near 90 percent success rate in improving quality of life, which included everything from decreased pain to increased survival rates. But the company acknowledged that the study was not peer-reviewed, and the results of their trial are not accepted by the American standards of science.
https://abcnews.go.com/Health/scorpion-venom-cure-ails/story?id=20755012

Fast Forward to 2021:

BURBANK, CA / ACCESSWIRE / January 27, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA) today announced In a recent study, a total of 400 patients in the Dominican Republic - where, a majority tested positive for COVID-19, and a small portion were COVID-19 symptomatic even though they tested negative for COVID-19 - reported a 100 percent improvement in symptoms after being administered Escozine®. Many of the patients participating in the study reported severe COVID-19 symptoms, such as difficulty breathing, pain and high fever, which Escozine® was able to relieve within 5 days of treatment. Even patients under ventilators were discharged within days, thanks to this novel product. Located in Santo Domingo, Dominican Republic, The Cruz Jiminian Clinic has carried out this ongoing study since August 2020, and has reported 0 COVID-19 related deaths after the clinic began administering Escozine®. Escozine®, produced by Medolife Rx, Inc., ("Medolife"), is a therapeutic consisting of small molecule peptides derived from a specific species of scorpions, Rhopalurus princeps, endemic to the Dominican Republic. After the successful study, Escozine® is on fast-track to be registered with the Ministry of Health in the Dominican Republic in Q1 2021. Medolife also submitted the study data to the US FDA, which is currently under review for permission to repeat the clinical trial in the United States. In addition to supporting the recovery of COVID-19 patients, Escozine® was registered and certified for cancer treatment by the Ministry of Health in the Dominican Republic in 2010.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163538871

Medolife Rx Announces Positive Pre-Clinical Results Showing Up to 95 Percent Cancer Cell Apoptosis with Introduction of Lead Cancer Drug Candidate
BURBANK, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today pre-clinical study results conducted at one of the leading cancer research centers in the United States showing that the Company’s lead drug candidate Escozine® caused up to 95 percent Specific Induced Apoptosis (SIA) in various types of Leukemia cancer cells. Such a result is significant not only to the Company’s ongoing clinical research, but could have tremendous effects on cancer treatments worldwide.
https://www.biospace.com/article/releases/medolife-rx-announces-positive-pre-clinical-results-showing-up-to-95-percent-cancer-cell-apoptosis-with-introduction-of-lead-cancer-drug-candidate/

Medolife Rx Submits Final Data Set to FDA for IND Filing on Lead Drug Candidate
BURBANK, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has filed its final set of data requested by the US Food and Drug Administration (FDA) for its Pre-Investigational New Drug (PIND #150335) filing on its lead drug candidate Escozine® as a COVID-19 therapeutic. Along with the submission of a batch of Escozine® previously announced specifically produced for the FDA, the Company believes that this will be the last submission necessary in order to receive IND designation from the regulatory body in the United States.
https://www.otcmarkets.com/stock/QNTA/news/story?e&id=1862474

No matter how GREAT one may think their technology is PROTOCOLS must be followed to get your product to the market in the biotech space.

ENZC time will come.